CADTH | Search

Current Filters

Showing 21 - 30 results of 3551

sacubitril/valsartan (Entresto) (Last Updated: Mar 29, 2021)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Indications

Brand Name:
Entresto
Manufacturer:
Novartis Pharma Inc.
Indications:

Entresto is indicated for the treatment of heart failure with reduced ejection fraction (HFrEF) in patients with NYHA Class II or III, to reduce the incidence of cardiovascular death and heart failure hospitalisation. Entresto should be administered in combination
with other heart failure therapies, in place of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin
II receptor blocker (ARB). Entresto should be initiated, and up-titration conducted, by
a physician experienced with the treatment of heart failure.

voretigene neparvovec (Luxturna) (Last Updated: Jan 14, 2021)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Luxturna
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Submission Type:
Initial
Indications:

​Indicated for the treatment of adult and pediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.

Health Technology Update Issue 26 (Last Updated: Jun 12, 2020)

This issue of Health Technology Update features brief summaries of information on a broad range of medical technologies — from a robotic wheelchair that uses gyroscope technology to a self-expanding...
Project Line:
Horizon Scan

Pembrolizumab (Keytruda) for HNSCC - Details (Keytruda ) (Last Updated: Jan 14, 2021)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indication

Brand Name:
Keytruda
Manufacturer:
Merck Canada
Submission Type:
Initial

New at CADTH — March 2020 (Last Updated: Mar 9, 2020)

News and Events After carefully considering the evolving situation with COVID-19, and keeping in mind the Public Health Agency of Canada’s advice on mass gatherings during the outbreak, we’ve made the...
Project Line:
New at CADTH

etonogestrel (Nexplanon) (Last Updated: Dec 8, 2020)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Nexplanon
Manufacturer:
Merck Canada Inc.
Submission Type:
Initial
Indications:

Indicated for the prevention of pregnancy for up to 3 years

Download results as CSV